Catalent, Inc. is specialized in pharmaceutical outsourcing services. The group offers solutions for the development and formulation of drugs, biological products and animal health products. Net sales break down by activity as follows: - provision of development services and clinical supply services (55.4%); - subcontracted manufacturing services (44.6%). Net sales are distributed geographically as follows: the United States (63.2%), Europe (28.7%) and other (8.1%).

Employees

16,900

Sector

Pharmaceuticals

Calendar

2024-11-04 - Q1 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
24-09-17	60.34 $	+0.31%	359,829
24-09-16	60.16 $	+0.91%	1,386,702
24-09-13	59.62 $	-0.12%	1,039,717
24-09-12	59.69 $	+0.10%	1,100,527
24-09-11	59.63 $	-0.20%	1,316,177

Delayed Quote Nyse, September 16, 2024 at 04:00 pm EDT

More quotes

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

60.16USD

Average target price

63.43USD

Spread / Average Target

+5.43%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

Real-time Estimate Cboe BZX Other stock markets 12:16:21 2024-09-17 pm EDT			5-day change	1st Jan Change
60.34 ^USD	+0.31%		+1.00%	+34.31%

Sep. 13	Eli Lilly invests $1.8 billion in Ireland sites to scale up Alzheimer's, obesity drug production	RE
Aug. 29	Sector Update: Health Care Stocks Advance Premarket Thursday	MT

Capitalization	10.92B	P/E ratio 2025 *	631x	P/E ratio 2026 *	87.9x
Enterprise value	14.79B	EV / Sales 2025 *	3.31x	EV / Sales 2026 *	3.01x
Free-Float	97.72%	Yield 2025 *	-	Yield 2026 *	-

Eli Lilly invests $1.8 billion in Ireland sites to scale up Alzheimer's, obesity drug production	Sep. 12	RE
Sector Update: Health Care Stocks Advance Premarket Thursday	Aug. 29	MT
Catalent Fiscal Q4 Adjusted Earnings, Net Revenue Climb	Aug. 29	MT
Earnings Flash (CTLT) CATALENT Reports Q4 Revenue $1.3B	Aug. 29	MT
Catalent, Inc. Reports Earnings Results for the Full Year Ended June 30, 2024	Aug. 29	CI
Catalent Insider Sold Shares Worth $534,011, According to a Recent SEC Filing	Jul. 30	MT
Catalent Completes $25 Million Expansion of Schorndorf Site	Jul. 16	MT
Catalent Completes $25 Million Expansion of Its Clinical Supply Facility in Schorndorf, Germany	Jul. 16	CI
Analyst recommendations: Albemarle, Snowflake, Tesla, Diageo, Johnson Matthey...	Jul. 12
Barclays Raises Catalent's Price Target to $63 From $47, Maintains Equalweight Rating	Jun. 28	MT
Barclays Adjusts Catalent Price Target to $63 From $47	Jun. 27	MT
Wegovy-maker Novo Nordisk to spend $4.1 bln to boost US manufacturing	Jun. 24	RE
Catalent Shareholders Approve Deal With Novo Holdings	May. 29	MT

Catalent Insider Sold Shares Worth $534,011, According to a Recent SEC Filing	Jul. 30	MT
Barclays Raises Catalent's Price Target to $63 From $47, Maintains Equalweight Rating	Jun. 28	MT
Barclays Adjusts Catalent Price Target to $63 From $47	Jun. 27	MT
Argus Downgrades Catalent to Sell From Buy	May. 16	MT
Novo Nordisk Plans First Bond Sale in 2 Years	May. 13	MT

Catalent, Inc. Stock

Equities

CTLT

US1488061029

Pharmaceuticals

Valuation: Catalent, Inc.

Chart: Catalent, Inc.

Latest news: Catalent, Inc.

Last Transcript: Catalent, Inc.

Analysts' recommendations: Catalent, Inc.

Press Releases: Catalent, Inc.

News in other languages: Catalent, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Catalent, Inc.

ETFs: Catalent, Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Ratings

Analysts' Consensus

Quarterly earnings, Rate of surprise

American Injectables CEO Beau Garrett Comments on the Catalent-Novo Transaction: A Catalyst for Competition and Innovation	Aug. 30	AQ
Catalent: Fiscal Q4 Earnings Snapshot	Aug. 29	AQ
Catalent, Inc. Reports Fourth Quarter and Fiscal 2024 Results	Aug. 29	BU
Catalent Completes $25 Million Expansion of its Clinical Supply Facility in Schorndorf, Germany	Jul. 16	BU
Ardena appoints Jeremie Trochu as Chief Executive Officer	Jun. 07	AQ

C'est mou du genou	Aug. 27
En Direct des Marchés : Eiffage, Technip Energies, Ipsen, Apple, Paramount, Sonova...	Aug. 27
Borsa di Italia: Morbida in ginocchio	Aug. 27
Bolsa de Madrid: Blandos de rodillas	Aug. 27
Fumée blanche à Jackson Hole	Aug. 26

1 day	+0.91%
1 week	+0.42%
Current month	-1.31%
1 month	+1.02%
3 months	+8.44%
6 months	+7.01%
Current year	+33.90%

Director	Title	Age	Since
Alessandro Maselli CEO	Chief Executive Officer	52	10-09-30
Matti Masanovich DFI	Director of Finance/CFO	52	23-07-04
Lim Chin Wei CTO	Chief Tech/Sci/R&D Officer	-	16-12-31

Manager	Title	Age	Since
Jack Stahl BRD	Director/Board Member	71	14-07-29
Rolf Classon BRD	Director/Board Member	79	14-07-31
Gregory Lucier BRD	Director/Board Member	59	15-03-31

Name	Weight	AuM	1st Jan change
BMO MSCI GENOMIC INNOVATION INDEX ETF - CAD	1.35%	2 M€	-.--%
FIRST TRUST ALPHADEX U.S. HEALTH CARE SECTOR INDEX ETF - CAD	1.21%	7 M€	0.00%
FIRST TRUST ALPHADEX U.S. HEALTH CARE SECTOR INDEX ETF - CAD HEDGED	0.83%	2 M€	+13.77%

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
CATALENT, INC.	+0.91%	+0.42%	+22.38%	-56.46%	10.92B
ELI LILLY AND COMPANY	-0.02%	+1.68%	+60.43%	+299.73%	832B
NOVO NORDISK A/S	+0.39%	+3.96%	+41.77%	+185.61%	609B
JOHNSON & JOHNSON	+0.89%	+0.23%	+3.43%	+1.07%	402B
ABBVIE INC.	+0.78%	-0.35%	+28.67%	+81.10%	346B
MERCK & CO., INC.	+2.49%	+2.21%	+9.71%	+63.90%	299B
ROCHE HOLDING AG	-0.56%	-1.16%	+1.05%	-23.48%	251B
ASTRAZENECA PLC	+0.74%	-5.48%	+9.84%	+47.60%	246B
NOVARTIS AG	+0.25%	-1.19%	+6.67%	+26.34%	236B
AMGEN INC.	+0.85%	+2.87%	+28.59%	+54.24%	180B
Average	+0.27%	+0.51%	+21.25%	+67.97%	341.19B
Weighted average by Cap.	+0.14%	+1.15%	+29.18%	+126.35%

	2025 *	2026 *
Net sales	4.72B	5.03B
Net income	40.93M	152M
Net Debt	4.69B	4.25B